Lv11
100 积分 2022-07-04 加入
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
1小时前
已完结
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer
1个月前
已完结
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
1个月前
已完结
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
3个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
5个月前
已完结
A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
5个月前
已完结
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
10个月前
已完结
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
10个月前
已完结
Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer
10个月前
已完结
The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences
10个月前
已完结
皖公网安备34019202002308
